SEC Form 4 · accession 0001193125-26-298558
Kailera Therapeutics, Inc. · KLRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathleen Tregoning
Officer — See Remarks
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002096997
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $23.30 | Jul 6, 2026 | A | 175,000 | A | — | Jul 6, 2036 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Remarks
Chief Corporate Affairs Officer